Law Firm Investigates Lifecore Biomedical Sale
Law firm Monteverde & Associates PC has initiated an investigation into Lifecore Biomedical's sale agreement, where shareholders are to receive cash and a right to contingent payments.
Monteverde & Associates PC, a law firm specializing in M&A class actions, announced on September 29, 2026, that it is investigating the sale of Lifecore Biomedical, Inc. (NASDAQ: LFCR) to affiliates of Webster Equity Partners.
The investigation stems from the terms of the proposed transaction. Under the agreement, Lifecore shareholders are expected to receive $6.28 in cash per share, along with a non-transferable contingent value right. This right entitles holders to potential additional cash payments based on the company achieving specified revenue and EBITDA milestones through 2030.
Monteverde & Associates PC, which has a track record of recovering funds for shareholders, aims to determine if the proposed deal adequately represents the interests of Lifecore's investors. The firm has provided a dedicated webpage for shareholders seeking more information.
Shareholders who own common stock in Lifecore Biomedical and have concerns are encouraged to contact Monteverde & Associates PC for additional details, free of charge and without obligation. Such investigations can sometimes lead to adjustments or additional compensation for shareholders if improprieties are found.